nach oben

Drugs

Erschienen in:

01.07.2009 | Adis Drug Profile

Ixabepilone

In Locally Advanced or Metastatic Breast Cancer

verfasst von: Marit D. Moen

Erschienen in: Drugs | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Abstract

▲ Ixabepilone, an analogue of the natural product epothilone B, stabilizes microtubules resulting in cell cycle arrest and apoptosis. It is indicated for the treatment of locally advanced or metastatic breast cancer in the US.
▲ Ixabepilone has shown antitumour activity in tumour cell lines in vitro and in several animal tumour models, including those that display key mechanisms of resistance to other anticancer agents.
▲ In a randomized, nonblind, multicentre, phase III trial in women with locally advanced or metastatic breast cancer that was pretreated with, or resistant to, anthracyclines and resistant to taxanes, progression-free survival was significantly longer in ixabepilone plus capecitabine recipients compared with recipients of capecitabine monotherapy (median 5.8 vs 4.2 months).
▲ The response rate to ixabepilone monotherapy was 11.5% in a noncomparative, multicentre, phase II trial in women with locally advanced or metastatic breast cancer resistant to anthracyclines, taxanes and capecitabine.
▲ The most common grade 3 or 4 treatment-related adverse events in both trials were myelosuppression and peripheral sensory neuropathy.

Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007 Feb; 18(2): 215–25PubMedCrossRef

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer V.I. 2009 [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf [Accessed 2009 Mar 4]

European School of Oncology (ESO)-MBC Task Force. Metastatic breast cancer: recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast 2007 Feb; 16(1): 9–10CrossRef

Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008 Jun; 34(4): 378–90PubMedCrossRef

Vahdat L. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Oncologist 2008 Mar; 13(3): 214–21PubMedCrossRef

Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol 2009 Jan; 63(2): 201–12PubMedCrossRef

Lee FY, Borzilleri R, Fairchild CR, et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol 2008 Dec; 63(1): 157–66PubMedCrossRef

Ixempra® Kit (ixabepilone) for injection: US prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2009 May

Denduluri N, Swain SM. Ixabepilone for the treatment of solid tumors: a review of clinical data. Expert Opin Investig Drugs 2008 Mar; 17(3): 423–35PubMedCrossRef

10.

Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin Breast Cancer 2007 Apr; 7(7): 543–9PubMedCrossRef

11.

Fumoleau P, Coudert B, Isambert N, et al. Novel tubulintargeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol 2007 Jul; 18 Suppl. 5: v9–15PubMedCrossRef

12.

Pivot X, Villanueva C, Chaigneau L, et al. Ixabepilone, a novel epothilone analog in the treatment of breast cancer. Expert Opin Investig Drugs 2008 Apr; 17(4): 593–9PubMedCrossRef

13.

Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001 May; 7(5): 1429–37PubMed

14.

McDaid HM, Mani S, Shen HJ, et al. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002 Jul; 8(7): 2035–43PubMed

15.

Zhuang SH, Hung YE, Hung L, et al. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone. Clin Cancer Res 2007 Dec 15; 13(24): 7480–6PubMedCrossRef

16.

Lee FY, Camuso A, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts [abstract no. 12017]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. Pt 1): 597s

17.

Baselga J, Zambetti M, Llombart-Cussac A, et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol 2009 Feb 1; 27(4): 526–34PubMedCrossRef

18.

Aghajanian 3rd C, Burris HA, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007 Mar 20; 25(9): 1082–8PubMedCrossRef

19.

Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004 Feb 15; 10(4): 1289–98PubMedCrossRef

20.

Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005 Sep 1; 11(17): 6233–9PubMedCrossRef

21.

Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003 May 1; 21(9): 1866–73PubMedCrossRef

22.

Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 2008 Apr; 61(5): 751–8PubMedCrossRef

23.

Takimoto CH, Liu PY, Lenz H, et al. A phase I pharmacokinetic study of the epothilone B analogue, ixabepilone (BMS-247550) in patients with advanced malignancies and varying degrees of hepatic impairment: a SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group Trial [abstract no. 2004]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. Pt 1): 80sCrossRef

24.

Goel S, Cohen M, Çömezoglu SN, et al. The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in latephase clinical development. Clin Cancer Res 2008 May 1; 14(9): 2701–9PubMedCrossRef

25.

Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007 Nov 20; 25(33): 5210–7PubMedCrossRef

26.

Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007 Aug 10; 25(23): 3407–14PubMedCrossRef

27.

Pivot XB, Lee RK, Thomas ES, et al. Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer resistant to anthracyclines/taxanes: subgroup analysis by estrogen receptor status [abstract no. 221]. 2007 Breast Cancer Symposium; 2007 Sep 7–8; San Francisco (CA)

28.

Rugo HS, Thomas ES, Lee RK, et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes [abstract no. 6069]. Breast Cancer Res Treat 2007 Dec; 106 Suppl. 1: S270. Plus poster presented at the 30th Annual San Antonio Breast Cancer Symposium; 2007 Dec 13–16; San Antonio (TX)

29.

Hortobagyi GN, Perez E, Vrdoljak E, et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials [abstract no. 186]. 2008 Breast Cancer Symposium; 2008 Sep 5–8; Washington, DC

30.

Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007 Aug 10; 25(23): 3415–20PubMedCrossRef

31.

Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007 Aug 10; 25(23): 3399–406PubMedCrossRef

32.

Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007 Aug 10; 25(23): 3421–7PubMedCrossRef

33.

Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005 Apr 20; 23(12): 2726–34PubMedCrossRef

34.

Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007 Feb; 25(1): 63–7PubMedCrossRef

35.

Reed SD, Li Y, Anstrom KJ, et al. Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2009 May 1; 27(13): 2185–91PubMedCrossRef

Titel: Ixabepilone
In Locally Advanced or Metastatic Breast Cancer
verfasst von: Marit D. Moen
Publikationsdatum: 01.07.2009
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 11/2009
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200969110-00006

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Ixabepilone

In Locally Advanced or Metastatic Breast Cancer

Abstract

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2009

Budesonide/Formoterol Pressurized Metered-Dose Inhaler

Etoricoxib

Endemic Fungal Infections in Patients Receiving Tumour Necrosis Factor-α Inhibitor Therapy

Streptokinase and Enoxaparin as an Alternative to Fibrin-Specific Lytic-Based Regimens

Rabbit Antithymocyte Globulin (Thymoglobulin®)

Statin Use and Risk of Colorectal Cancer in a Cohort of Middle-Aged Men in the US